

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re

U.S. application of:

Dr. Kenneth Fine

For:

**METHOD FOR DIAGNOSING IMMUNOLOGIC FOOD
SENSITIVITY**

U.S. Serial No.:

10/670,100

Filed:

September 24, 2003

Group Art Unit:

3661

MAILSTOP NON FEE AMENDMENT

Commissioner for

Patents

P.O. Box 1450

Alexandria, VA 22313-1450

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: MAIL STOP NON FEE AMENDMENT Commissioner for Patents, P.O. Box 1450 Alexandria, VA, on

January 13, 2004
Angela Wilson
Angela Wilson

Dear Sir:

INFORMATION DISCLOSURE STATEMENT

Pursuant to the provisions of 37 C.F.R. § 1.97, Applicant hereby makes of record the references set forth in the attached PTO form SB/08. No inference should be made that the cited references are in fact material, are in fact prior art, or that no better art exists. The cited patents are listed in the same order as they were listed in the Information Disclosure Statement for the parent application and not in any order based on their pertinence.

Pursuant to 37 C.F.R. § 1.98(d) no copies of the cited references are enclosed since the references were provided in the parent application, U. S. Serial No. **09/798,557, filed on March 2, 2001.**

No representation is made, and no representation is intended, that more relevant material does not exist, or that the order of presentation of this material in any way reflects the relative pertinence. The references cited are not intended to constitute an admission of any kind. Specifically, this


presentation is not an admission that the items listed are properly citable against the above-identified application.

As this Information Disclosure Statement is being filed before the mailing of a first Office Action, it is believed no fee is due. However, if any fee (other than an issue fee) is required or any refund issued during pendency of this U. S. patent application, please charge it to Deposit Account 50-2180 of Paul Storm, P.C.

It is requested that the Examiner fully consider the cited references and that they be cited on the front of any patent issuing from this application.

Respectfully submitted,

STORM & HEMINGWAY, L.L.P.



Dawn C. Wolff
Reg. No. 48,695

1-13-04
Date

8117 Preston Road
Suite 460
Dallas, TX 75225
214.292.8996
214.292.8999 (fax)

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.**



Please type a plus sign (+) inside this box →



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 4

Complete if Known

Application Number	10/670,100
Filing Date	September 24, 2003
First Named Inventor	Dr. Kenneth D. Fine
Group Art Unit	3661
Examiner Name	Nguyen, Bai Thuy L.
Attorney Docket Number	FINE 01936 C1US

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	AA	PICARELLI, Antonio, et al.; Gluten-Sensitive Disease with Mild Enteropathy; Gastroenterology 1996; 111; pp 608-616.	
	AB	COOPER, B. T., et al.; Gluten-Sensitive Diarrhea Without Evidence of Celiac Disease; Gastroenterology 1980; 79; pp 801-806.	
	AC	MAIURI L., et al.; Definition of the Initial Immunologic Modifications Upon in Vitro Gliadin Challenge in the Small Intestine of Celiac Patients; Gastroenterology 1966; 110; pp 1368-1378.	
	AD	FERGUSON, A., et al.; Clinical and Pathological Spectrum of Coeliac Disease - Active, silent, latent, potential; Gut 1993; 34; pp 150-151.	
	AE	VENTURA, Alessandro, et al.; Duration of Exposure to Gluten and Risk for Autoimmune Disorders in Patients with Celiac Disease; Gastroenterology 1999 Aug; 117(2); pp 297-303.	
	AF	FINE, Kenneth D., et al.; The Genetic and Histopathologic Relationship of Microscopic Colitis and Celiac Sprue or Refractory Sprue; Gastroenterology 1999; 116; A879. (Abstract)	
	AG	FINE, Kenneth D., et al.; High Prevalence of Celiac Sprue-Like HLA-DQ Genes and Enteropathy in Patients with the Microscopic Colitis Syndrome; Am J Gastroenterol 2000; 95; pp 1974-1982	
	AH	FINE, Kenneth D., et al.; The Prevalence and Causes of Chronic Diarrhea in Patients with Celiac Sprue Treated with a Gluten-Free Diet; Gastroenterology 1997; 112; pp 1830-1837.	
	AI	FINE, Kenneth D., et al.; Colonic Histopathology in Untreated Celiac Sprue or Refractory Sprue: Is it Lymphocytic Colitis or Colonic Lymphocytosis?; Human Pathology 1998; 29; pp 1433-1440.	
	AJ	O'Mahony, S., et al.; Dissociation Between Systemic and Mucosal Humoral Immune Responses in Coeliac Disease; Gut; 1991; Jan; 32(1) pp 29-235.	
	AK	DICKEY, W., et al.; Reliance on Serum Endomysial Antibody Testing Underestimates the True Prevalence of Coeliac Disease by One Fifth; Scand J. Gastroenterol 2000; Feb(2); 181-183. Review.	

Examiner
Signature

Date
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Please place a plus sign (+) inside this box →

+

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 3 of 4

Complete if Known

Application Number	10/670,100
Filing Date	September 24, 2003
First Named Inventor	Dr. Kenneth D. Fine
Group Art Unit	3661
Examiner Name	Nguyen, Bai Thuy L.
Attorney Docket Number	FINE 01936 C1US

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	AL	ROSTAMI, Kamran, et al.; Sensitivity of Antiendomysium and Antigliadin Antibodies in Untreated Celiac Disease; Am J Gastroenterol; 1999; Apr; 94(4); pp 888-894.	
	AM	GREEN, PHR, et al; Detection of Antiendomysial Antibodies in Adult Celiacs Depends on Histologic and Clinical Disease Severity; Gastroenterology; 116; A883; Abstract.	
	AN	PRASAD, Shyam, et al.; Adult Endomysial Antibody-Negative Coeliac Disease and Cigarette Smoking; Eur J Gastroenterol Hepatol; 2001; Jun; 13(6); pp 667-671.	
	AO	DIETERICH, Walburga, et al.; Autoantibodies to Tissue Transglutaminase as Predictors of Celiac Disease; Gastroenterology 1998; 115; pp 1317-1321.	
	AP	SULKANEN, Satu, et al.; Tissue Transglutaminase Autoantibody Enzyme-Linked Immunosorbent Assay in Detecting Celiac Disease; Gastroenterology 1998; 115; pp 1322-1328.	
	AQ	TRONCONE, Ricardo, et al.; Anti-Gliadin Antibodies; J Pediatric Gastroenterol Nutr 1991; 12; pp 150-158.	
	AR	ANDRE F, et al.; IgE in Stools as Indicator of Food Sensitization; Apr; 50(4); 328-333.	
	AS	SASAI, K., et al.; Fecal IgE Levels in Infants at 1 Month of Age as Indicator of Atopic Disease; Allergy; 1994; Oct; 49(49); pp 791-794.	
	AT	KOLMANNKOG, S., et al.; Immunoglobulin E in Extracts of Feces from Children; Inter. Archives of Allergy and Applied Immunology; 1984; 74(1); pp 50-54.	
	AU	KOLMANNKOG, S., et al.; The Excretion of IgE with Feces from Healthy Individuals and from Others with Allergy and Diseases Affecting the Intestinal Tract; Int. Archives of Allergy and Applied Immunology; 1986; 79(4); pp 357-364.	
	AV	VADEN, Shelly, et al.; Food Hypersensitivity Reactions in Soft Coated Wheat Terriers with Protein-Losing Enteropathy or Protein-Losing Nephropathy or Both; Gastroscopic Food Sensitivity Testing, Dietary Provocation, and Fecal Immunoglobulin E; J Vet Inter. Med. 2000; Jan-Feb; 14(1); pp 60-67.	

Examiner
Signature

Date
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Please type a plus sign (+) inside this box →



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 4 of 4

Complete if Known

Application Number	10/670,100
Filing Date	September 24, 2003
First Named Inventor	Dr. Kenneth D. Fine
Group Art Unit	3661
Examiner Name	Nguyen, Bai Thuy L.
Attorney Docket Number	FINE 01936 C1US

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	AW	KOLMANNSSKOG, S, et al.; Immunoglobulin E in Feces from Children with Allergy. Evidence of Local Production of IgE in the gut; International Archives Allergy Applied Immunology; 1985; 76(2); pp 133-137.	
	AX	HAAS, L., et al.; Increased Concentrations of Fecal Anti-Gliadin IGA Antibodies in Untreated Celiac Disease; Clinical Chemistry; 1993; April; 39(4); pp 696-697.	
	AY	PICARELLI, Antonio et al.; Antiendomysial Antibody Detection in Fecal Supernatants; Gastroenterology 2000; 118; A 370; Vol. 118; No. 4.	
	BG		

Examiner
Signature

Date
Considered

¹ EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.